{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:08Z","timestamp":1792788188551,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Council","award":["K013351"],"award-info":[{"award-number":["K013351"]}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"crossref","award":["ANR-19-CE36-0004-01"],"award-info":[{"award-number":["ANR-19-CE36-0004-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Approximately 25% of the general population carries at least one \u03b54 allele of the Apolipoprotein E (\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54), the strongest genetic risk factor for late onset Alzheimer\u2019s disease. Beyond its association with late-onset dementia, the association between\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 and change in cognition over the adult life course remains uncertain. This study aims to examine whether the association between Apolipoprotein E (\n                      <jats:italic>APOE<\/jats:italic>\n                      ) \u03b54 zygosity and cognition function is modified between midlife and old age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cohort study of 5561 participants (mean age 55.5 (SD\u2009=\u20095.9) years, 27.1% women) with\n                      <jats:italic>APOE<\/jats:italic>\n                      genotyping and repeated cognitive tests for reasoning, memory, and semantic and phonemic fluency, during a mean (SD) follow-up of 20.2 (2.8) years (the Whitehall II study). We used joint models to examine the association of\n                      <jats:italic>APOE<\/jats:italic>\n                      genotype with cognitive function trajectories between 45 and 85\u2009years taking drop-out, dementia, and death into account and Fine and Gray models to examine associations with dementia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to non-carriers, heterozygote (prevalence 25%) and homozygote (prevalence 2%)\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 carriers had increased risk of dementia, sub-distribution hazard ratios 2.19 (95% CI 1.73, 2.77) and 5.97 (95% CI 3.85, 9.28) respectively. Using data spanning 45\u201385\u2009years with non-\u03b54 carriers as the reference, \u03b54 homozygotes had poorer global cognitive score starting from 65\u2009years; \u03b54 heterozygotes had better scores between 45 and 55\u2009years, then no difference until poorer cognitive scores from 75\u2009years onwards. In analysis of individual cognitive tests, better cognitive performance in the younger \u03b54 heterozygotes was primarily attributable to executive function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Both heterozygous and homozygous \u03b54 carriers had poorer cognition and greater risk of dementia at older ages. Our findings show some support for a complex antagonist pleiotropic effect of\n                      <jats:italic>APOE<\/jats:italic>\n                      \u03b54 heterozygosity over the adult life course, characterized by cognitive advantage in midlife.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00740-0","type":"journal-article","created":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T13:02:59Z","timestamp":1609765379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":177,"title":["The association of APOE \u03b54 with cognitive function over the adult life course and incidence of dementia: 20\u2009years follow-up of the Whitehall II study"],"prefix":"10.1186","volume":"13","author":[{"given":"Amin","family":"Gharbi-Meliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Dugravot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Sabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina","family":"Regy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Fayosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Schnitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kivim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Singh-Manoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2070-9706","authenticated-orcid":false,"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"740_CR1","doi-asserted-by":"crossref","unstructured":"Dumurgier J, Tzourio C. Epidemiology of neurological diseases in older adults. Rev Neurol (Paris). 2020;176:642\u20138.","DOI":"10.1016\/j.neurol.2020.01.356"},{"key":"740_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1046\/j.1469-1809.1999.6340301.x","volume":"63","author":"RM Corbo","year":"1999","unstructured":"Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a \u2018thrifty\u2019 allele? Ann Hum Genet. 1999;63:301\u201310.","journal-title":"Ann Hum Genet"},{"key":"740_CR3","doi-asserted-by":"publisher","first-page":"e1003289","DOI":"10.1371\/journal.pmed.1003289","volume":"17","author":"H Saddiki","year":"2020","unstructured":"Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E genotype and Alzheimer disease: a cerebrospinal fluid biomarker-based case-control study. Plos Med. 2020;17:e1003289.","journal-title":"Plos Med"},{"key":"740_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/mp.2013.194","volume":"19","author":"C Conejero-Goldberg","year":"2014","unstructured":"Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, et al. APOE2 enhances neuroprotection against Alzheimer\u2019s disease through multiple molecular mechanisms. Mol Psychiatry. 2014;19:1243\u201350.","journal-title":"Mol Psychiatry"},{"key":"740_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-020-00628-z","volume":"12","author":"E Konijnenberg","year":"2020","unstructured":"Konijnenberg E, Tijms BM, Gobom J, et al. APOE \u03b54 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:65.","journal-title":"Alzheimers Res Ther"},{"key":"740_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13195-018-0411-x","volume":"10","author":"D Yi","year":"2018","unstructured":"Yi D, Lee Y, Byun MS, et al. Synergistic interaction between APOE and family history of Alzheimer\u2019s disease on cerebral amyloid deposition and glucose metabolism. Alzheimers Res Ther. 2018;10:84.","journal-title":"Alzheimers Res Ther"},{"key":"740_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jalz.2016.05.003","volume":"12","author":"X Sun","year":"2016","unstructured":"Sun X, Dong C, Levin B, et al. APOE epsilon4 carriers may undergo synaptic damage conferring risk of Alzheimer\u2019s disease. Alzheimers Dement. 2016;12:1159\u201366.","journal-title":"Alzheimers Dement"},{"key":"740_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ana.25455","volume":"85","author":"AR Wadhwani","year":"2019","unstructured":"Wadhwani AR, Affaneh A, Van Gulden S, Kessler JA. Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease. Ann Neurol. 2019;85:726\u201339.","journal-title":"Ann Neurol"},{"key":"740_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3233\/JAD-150862","volume":"53","author":"OA Skrobot","year":"2016","unstructured":"Skrobot OA, McKnight AJ, Passmore PA, et al. A validation study of vascular cognitive impairment genetics meta-analysis findings in an independent collaborative cohort. J Alzheimers Dis. 2016;53:981\u20139.","journal-title":"J Alzheimers Dis"},{"key":"740_CR10","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1038\/s41598-019-43458-2","volume":"9","author":"A Rongve","year":"2019","unstructured":"Rongve A, Witoelar A, Ruiz A, et al. GBA and APOE epsilon4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Sci Rep. 2019;9:7013.","journal-title":"Sci Rep"},{"key":"740_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cortex.2018.03.025","volume":"104","author":"MC O\u2019Donoghue","year":"2018","unstructured":"O\u2019Donoghue MC, Murphy SE, Zamboni G, Nobre AC, Mackay CE. APOE genotype and cognition in healthy individuals at risk of Alzheimer\u2019s disease: a review. Cortex. 2018;104:103\u201323.","journal-title":"Cortex."},{"key":"740_CR12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/WCO.0000000000000262","volume":"28","author":"G Salvato","year":"2015","unstructured":"Salvato G. Does apolipoprotein E genotype influence cognition in middle-aged individuals? Curr Opin Neurol. 2015;28:612\u20137.","journal-title":"Curr Opin Neurol"},{"key":"740_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1212\/WNL.0b013e3182167147","volume":"76","author":"RJ Caselli","year":"2011","unstructured":"Caselli RJ, Dueck AC, Locke DE, et al. Longitudinal modeling of frontal cognition in APOE epsilon4 homozygotes, heterozygotes, and noncarriers. Neurology. 2011;76:1383\u20138.","journal-title":"Neurology."},{"key":"740_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMoa0809437","volume":"361","author":"RJ Caselli","year":"2009","unstructured":"Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361:255\u201363.","journal-title":"N Engl J Med"},{"key":"740_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41398-017-0064-8","volume":"8","author":"MJ Rawle","year":"2018","unstructured":"Rawle MJ, Davis D, Bendayan R, Wong A, Kuh D, Richards M. Apolipoprotein-E (Apoe) epsilon4 and cognitive decline over the adult life course. Transl Psychiatry. 2018;8:18.","journal-title":"Transl Psychiatry"},{"key":"740_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0304-3940(00)01569-X","volume":"294","author":"YW Yu","year":"2000","unstructured":"Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ. Intelligence and event-related potentials for young female human volunteer apolipoprotein E epsilon4 and non-epsilon4 carriers. Neurosci Lett. 2000;294:179\u201381.","journal-title":"Neurosci Lett"},{"key":"740_CR17","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1093\/cercor\/bhl103","volume":"17","author":"CR Mondadori","year":"2007","unstructured":"Mondadori CR, de Quervain DJ, Buchmann A, et al. Better memory and neural efficiency in young apolipoprotein E epsilon4 carriers. Cereb Cortex. 2007;17:1934\u201347.","journal-title":"Cereb Cortex"},{"key":"740_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.biopsycho.2007.03.001","volume":"75","author":"DM Alexander","year":"2007","unstructured":"Alexander DM, Williams LM, Gatt JM, et al. The contribution of apolipoprotein E alleles on cognitive performance and dynamic neural activity over six decades. Biol Psychol. 2007;75:229\u201338.","journal-title":"Biol Psychol"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2018.10.011","volume":"75","author":"A Bussy","year":"2019","unstructured":"Bussy A, Snider BJ, Coble D, et al. Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. Neurobiol Aging. 2019;75:42\u201350.","journal-title":"Neurobiol Aging"},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.08.009","volume":"94","author":"GH Weissberger","year":"2018","unstructured":"Weissberger GH, Nation DA, Nguyen CP, Bondi MW, Han SD. Meta-analysis of cognitive ability differences by apolipoprotein e genotype in young humans. Neurosci Biobehav Rev. 2018;94:49\u201358.","journal-title":"Neurosci Biobehav Rev"},{"key":"740_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2307\/2406060","volume":"11","author":"GC Williams","year":"1957","unstructured":"Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957;11:398\u2013411.","journal-title":"Evolution."},{"key":"740_CR22","doi-asserted-by":"crossref","first-page":"726197","DOI":"10.4061\/2011\/726197","volume":"2011","author":"ER Tuminello","year":"2011","unstructured":"Tuminello ER, Han SD. The apolipoprotein E antagonistic pleiotropy hypothesis: review and recommendations. Int J Alzheimers Dis. 2011;2011:726197.","journal-title":"Int J Alzheimers Dis"},{"key":"740_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2008.02.006","volume":"4","author":"SD Han","year":"2008","unstructured":"Han SD, Bondi MW. Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. Alzheimers Dement. 2008;4:251\u20134.","journal-title":"Alzheimers Dement"},{"key":"740_CR24","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/0140-6736(91)93068-K","volume":"337","author":"MG Marmot","year":"1991","unstructured":"Marmot MG, Smith GD, Stansfeld S, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337:1387\u201393.","journal-title":"Lancet."},{"key":"740_CR25","volume-title":"AH 4 group test of general intelligence","year":"1970","unstructured":"Heim AW, editor. AH 4 group test of general intelligence. Windsor: NFER-NelsonPublishing Company Ltd.; 1970."},{"key":"740_CR26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1212\/WNL.0b013e3181f39adc","volume":"75","author":"RS Wilson","year":"2010","unstructured":"Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis of age-related cognitive decline. Neurology. 2010;75:1070\u20138.","journal-title":"Neurology."},{"key":"740_CR27","doi-asserted-by":"publisher","first-page":"l4414","DOI":"10.1136\/bmj.l4414","volume":"366","author":"S Sabia","year":"2019","unstructured":"Sabia S, Fayosse A, Dumurgier J, et al. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. BMJ. 2019;366:l4414.","journal-title":"BMJ."},{"key":"740_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1750-1326-5-23","volume":"5","author":"S Sabia","year":"2010","unstructured":"Sabia S, Kivimaki M, Kumari M, Shipley MJ, Singh-Manoux A. Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife. Mol Neurodegener. 2010;5:23.","journal-title":"Mol Neurodegener"},{"key":"740_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"740_CR30","doi-asserted-by":"publisher","first-page":"E1033","DOI":"10.1503\/cmaj.180066","volume":"190","author":"KL Rasmussen","year":"2018","unstructured":"Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Absolute 10-year risk of dementia by age, sex and APOE genotype: a population-based cohort study. CMAJ. 2018;190:E1033\u2013e41.","journal-title":"CMAJ."},{"key":"740_CR31","doi-asserted-by":"publisher","first-page":"e1002254","DOI":"10.1371\/journal.pmed.1002254","volume":"14","author":"J Qian","year":"2017","unstructured":"Qian J, Wolters FJ, Beiser A, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med. 2017;14:e1002254.","journal-title":"PLoS Med"},{"key":"740_CR32","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/archneur.1997.00550210044011","volume":"54","author":"K Yaffe","year":"1997","unstructured":"Yaffe K, Cauley J, Sands L, Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997;54:1110\u20134.","journal-title":"Arch Neurol"},{"key":"740_CR33","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1212\/WNL.0b013e31826e9ae6","volume":"79","author":"YY Lim","year":"2012","unstructured":"Lim YY, Ellis KA, Pietrzak RH, et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79:1645\u201352.","journal-title":"Neurology."},{"key":"740_CR34","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1212\/01.wnl.0000286941.74372.cc","volume":"70","author":"MR Schultz","year":"2008","unstructured":"Schultz MR, Lyons MJ, Franz CE, et al. Apolipoprotein E genotype and memory in the sixth decade of life. Neurology. 2008;70:1771\u20137.","journal-title":"Neurology."},{"key":"740_CR35","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama. 2015;313:1924\u201338.","journal-title":"Jama."},{"key":"740_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neurobiolaging.2020.06.001","volume":"95","author":"SC Burnham","year":"2020","unstructured":"Burnham SC, Laws SM, Budgeon CA, et al. Impact of APOE-\u03b54 carriage on the onset and rates of neocortical A\u03b2-amyloid deposition. Neurobiol Aging. 2020;95:46\u201355.","journal-title":"Neurobiol Aging"},{"key":"740_CR37","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, et al. Association of Apolipoprotein E \u03b54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol. 2020;77:470\u20139.","journal-title":"JAMA Neurol"},{"key":"740_CR38","doi-asserted-by":"publisher","unstructured":"Weigand AJ, Thomas KR, Bangen KJ, et al. APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia. Alzheimers Dement. 2020. https:\/\/doi.org\/10.1002\/alz.12173.","DOI":"10.1002\/alz.12173"},{"key":"740_CR39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13195-020-00710-6","volume":"12","author":"MS Baek","year":"2020","unstructured":"Baek MS, Cho H, Lee HS, Lee JH, Ryu YH, Lyoo CH. Effect of APOE \u03b54 genotype on amyloid-\u03b2 and tau accumulation in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:140.","journal-title":"Alzheimers Res Ther"},{"key":"740_CR40","doi-asserted-by":"publisher","first-page":"832.e15","DOI":"10.1016\/j.neurobiolaging.2011.07.016","volume":"33","author":"HM Jochemsen","year":"2012","unstructured":"Jochemsen HM, Muller M, van der Graaf Y, Geerlings MI. APOE epsilon4 differentially influences change in memory performance depending on age. The SMART-MR study. Neurobiol Aging. 2012;33:832.e15\u201322.","journal-title":"Neurobiol Aging"},{"key":"740_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2012.12.043","volume":"243","author":"PH Moreau","year":"2013","unstructured":"Moreau PH, Bott JB, Zerbinatti C, et al. ApoE4 confers better spatial memory than apoE3 in young adult hAPP-Yac\/apoE-TR mice. Behav Brain Res. 2013;243:1\u20135.","journal-title":"Behav Brain Res"},{"key":"740_CR42","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jagp.2013.12.173","volume":"22","author":"D Yi","year":"2014","unstructured":"Yi D, Lee DY, Sohn BK, et al. Beta-amyloid associated differential effects of APOE epsilon4 on brain metabolism in cognitively normal elderly. Am J Geriatr Psychiatry. 2014;22:961\u201370.","journal-title":"Am J Geriatr Psychiatry"},{"key":"740_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13195-020-00702-6","volume":"12","author":"A Rubinski","year":"2020","unstructured":"Rubinski A, Franzmeier N, Neitzel J, Ewers M. FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels. Alzheimers Res Ther. 2020;12:133.","journal-title":"Alzheimers Res Ther"},{"key":"740_CR44","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-017-01150-x","volume":"8","author":"S Palmqvist","year":"2017","unstructured":"Palmqvist S, Scholl M, Strandberg O, et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8:1214.","journal-title":"Nat Commun"},{"key":"740_CR45","doi-asserted-by":"crossref","unstructured":"Abondio P, Sazzini M, Garagnani P, et al. The genetic variability of APOE in different human populations and its implications for longevity. Genes (Basel). 2019;10:222.","DOI":"10.3390\/genes10030222"},{"issue":"Suppl 1","key":"740_CR46","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1073\/pnas.0909606106","volume":"107","author":"CE Finch","year":"2010","unstructured":"Finch CE. Evolution in health and medicine Sackler colloquium: evolution of the human lifespan and diseases of aging: roles of infection, inflammation, and nutrition. Proc Natl Acad Sci U S A. 2010;107(Suppl 1):1718\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"740_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13195-020-00608-3","volume":"12","author":"J de Frutos-Lucas","year":"2020","unstructured":"de Frutos-Lucas J, Cuesta P, L\u00f3pez-Sanz D, et al. The relationship between physical activity, apolipoprotein E \u03b54 carriage, and brain health. Alzheimers Res Ther. 2020;12:48.","journal-title":"Alzheimers Res Ther"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-020-00740-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00740-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T15:07:35Z","timestamp":1724166455000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00740-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00740-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Participant consent and research ethics approvals are renewed at each contact; the latest approval was by the National Health Service (NHS) London\u2014Harrow Research Ethics Committee, reference number 85\/0938. All participants provided written, informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}